Senseonics (NYSE:SENS) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research report report published on Sunday. The firm issued a sell rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Senseonics in a report on Friday, November 15th.

Senseonics Price Performance

Shares of Senseonics stock opened at $0.30 on Friday. Senseonics has a one year low of $0.28 and a one year high of $0.75. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The stock’s 50-day moving average is $0.34 and its 200 day moving average is $0.39. The firm has a market cap of $179.49 million, a price-to-earnings ratio of -2.34 and a beta of 0.79.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Senseonics by 0.7% in the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after purchasing an additional 155,715 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Senseonics by 3.2% during the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after acquiring an additional 179,103 shares during the last quarter. Symmetry Partners LLC purchased a new stake in shares of Senseonics during the third quarter valued at approximately $164,000. Cubist Systematic Strategies LLC grew its holdings in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after purchasing an additional 51,000 shares during the period. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.